The purpose of this study is to learn about the effects of cadisegliatin (also called “TTP399”) compared to placebo to find out if or how much cadisegliatin may reduce the episodes of low blood sugar (hypoglycemia) in T1DM, or lower HbA1c, and to see how people with T1DM feel and do when taking cadisegliatin (how the study drug is tolerated).
We are doing this study to learn more about a new drug called AZD7760 when it is given as an intravenous (IV; into the vein) infusion to healthy adults (Phase I) or adults with end‑stage kidney disease who are on hemodialysis with a central venous catheter (Phase IIa).
We are doing this study to learn more about how effective, safe and tolerable an experimental drug called balcinrenone is when used in combination with dapagliflozin for treating patients with heart failure and impaired kidney function and also to better understand the studied disease and associated health problems.
We are doing this study to learn more about an experimental drug called AZD1613, and also to better understand ADPKD and associated health problems.
